Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
-
Date: September 09, 2021 Time: 8:00am (PDT), 11:00am (EDT) Human pluripotent stem cells (PSCs) hold great potentials in regenerative therapies. In this webinar, Chao will first present the c...
Date: July 07, 2021 Time: 8:00am (PDT), 11:00am (EDT) The DNA damage response is extremely crucial in maintaining genomic integrity. Failure to repair damaged DNA can result in the propagati...
Though tumor targeting using chimeric receptors (CAR) engineered to bind tumor-associated surface proteins such as CD19 in B cells have demonstrated remarkable efficacy in cancer, this thera...
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
Gene editing technologies such as CRISPR/Cas9 have greater flexibility and high efficiency. CRISPR technology enables targeted insertion of transgenes at the desired locus and has the abilit...
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...
Date: July 01, 2021 Time: 09:30am IST/12:00pm SGT/01:00pm JST, KST/03:00pm AEST/ 05:00pm NZST We know that understanding cell culture is essential for life of your work. Gibco Galaxy Tour We...
Date: June 23, 2021 Time: 9:00am PDT Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and...
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of thi...
Over the past 25 years, Luminex’s xMAP® Technology has emerged as the worldwide leader in bead-based multiplexing. The new xMAP® INTELLIFLEX platform combines the proven perfor...